^
Association details:
| Biomarker: | ROS1 fusion + KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway
Published date:
01/23/2023
Excerpt:
...we report on a patient with metastatic NSCLC with a concurrent ROS1 fusion and KRAS p.G12C mutation at diagnosis who experienced a short duration of disease control on entrectinib, a ROS1 TKI.
DOI:
https://doi.org/10.1038/s41698-023-00349-0
